Monoclonal antibodies for emerging infectious diseases - Borrowing from history

New England Journal of Medicine

Volumn 378, Issue 16, 2018, Pages 1469-1472

  Marston, Hilary D ^a   Paules, Catharine I ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

CLINICAL OUTCOME; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; EPIDEMIC; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFECTION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ANIMAL; COMMUNICABLE DISEASE; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; PREVENTION AND CONTROL; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; DISEASE TRANSMISSION, INFECTIOUS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOTHERAPY; MICE;

EID: 85045841784     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1802256     Document Type: Review

References (5)

1. Walker LM, Burton DR. Passive immunotherapy of viral infections: 'super-antibodies' enter the fray. Nat Rev Immunol 2018 January 30 (Epub ahead of print).
2. Sapparapu G, Fernandez E, Kose N, et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 2016; 540: 443-7.
3. The PREVAIL II Writing Group. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 2016; 375: 1448-56.
4. Mire CE, Geisbert TW. Neutralizing the threat: pan-ebolavirus antibodies close the loop. Trends Mol Med 2017; 23: 669-71.
5. Paules CI, Lakdawala S, McAuliffe JM, et al. The hemagglutinin A stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses. J Infect Dis 2017; 216: 356-65.